tetano
Editor, Senior Moderator
J Clin Med Res
. 2021 Sep;13(9):474-478.
doi: 10.14740/jocmr4579. Epub 2021 Sep 30.
Evaluation of Plasma Soluble Urokinase Plasminogen Activator Receptor Levels in Patients With COVID-19 and Non-COVID-19 Pneumonia: An Observational Cohort Study
Dimitrios Velissaris[SUP] 1 [/SUP], Maria Lagadinou[SUP] 1 [/SUP], Themistoklis Paraskevas[SUP] 1 [/SUP], Eleousa Oikonomou[SUP] 1 [/SUP], Vasileios Karamouzos[SUP] 2 [/SUP], Sofia Karteri[SUP] 3 [/SUP], Dimitrios Bousis[SUP] 1 [/SUP], Nikolaos Pantzaris[SUP] 4 [/SUP], Konstantinos Tsiotsios[SUP] 5 [/SUP], Markos Marangos[SUP] 1 [/SUP]
Affiliations
Abstract
Background: The respiratory system is the main system affected by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and a great number of infected people need hospitalization. Soluble urokinase plasminogen activator receptor (suPAR) is a biomarker indicative of acute and chronic inflammation. Current literature supports that suPAR has great predictive ability for mortality in patients with coronavirus disease 2019 (COVID-19). The aim of this study was to compare the value of suPAR and other laboratory biomarkers in patients with chest infection and suspected COVID-19.
Methods: A total of 41 consecutive patients with chest infection were enrolled in the study and were assigned into two groups according to the real-time polymerase chain reaction (PCR) result for SARS-CoV-2. The two groups had no significant difference in baseline data (age, sex), arterial oxygen partial pressure (PO[SUB]2[/SUB])/fraction of inspired oxygen (FiO[SUB]2[/SUB]) ratio and mortality.
Results: Among patients with chest infection who required hospitalization, suPAR was significantly higher on admission in those with COVID-19 when compared to patients with non-COVID-19. suPAR had a great prognostic ability for in-hospital mortality in the COVID-19 subgroup.
Conclusions: A single measurement of suPAR on admission can provide prognostic information for patients with suspected COVID-19 pneumonia. In the subgroup of patients with positive real-time PCR result for SARS-CoV2, suPAR was significantly higher and had an excellent prognostic value for the in-hospital mortality.
Keywords: Biomarker; COVID-19; Chest infection; Prognosis; suPAR.
. 2021 Sep;13(9):474-478.
doi: 10.14740/jocmr4579. Epub 2021 Sep 30.
Evaluation of Plasma Soluble Urokinase Plasminogen Activator Receptor Levels in Patients With COVID-19 and Non-COVID-19 Pneumonia: An Observational Cohort Study
Dimitrios Velissaris[SUP] 1 [/SUP], Maria Lagadinou[SUP] 1 [/SUP], Themistoklis Paraskevas[SUP] 1 [/SUP], Eleousa Oikonomou[SUP] 1 [/SUP], Vasileios Karamouzos[SUP] 2 [/SUP], Sofia Karteri[SUP] 3 [/SUP], Dimitrios Bousis[SUP] 1 [/SUP], Nikolaos Pantzaris[SUP] 4 [/SUP], Konstantinos Tsiotsios[SUP] 5 [/SUP], Markos Marangos[SUP] 1 [/SUP]
Affiliations
- PMID: 34691321
- PMCID: PMC8510652
- DOI: 10.14740/jocmr4579
Abstract
Background: The respiratory system is the main system affected by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and a great number of infected people need hospitalization. Soluble urokinase plasminogen activator receptor (suPAR) is a biomarker indicative of acute and chronic inflammation. Current literature supports that suPAR has great predictive ability for mortality in patients with coronavirus disease 2019 (COVID-19). The aim of this study was to compare the value of suPAR and other laboratory biomarkers in patients with chest infection and suspected COVID-19.
Methods: A total of 41 consecutive patients with chest infection were enrolled in the study and were assigned into two groups according to the real-time polymerase chain reaction (PCR) result for SARS-CoV-2. The two groups had no significant difference in baseline data (age, sex), arterial oxygen partial pressure (PO[SUB]2[/SUB])/fraction of inspired oxygen (FiO[SUB]2[/SUB]) ratio and mortality.
Results: Among patients with chest infection who required hospitalization, suPAR was significantly higher on admission in those with COVID-19 when compared to patients with non-COVID-19. suPAR had a great prognostic ability for in-hospital mortality in the COVID-19 subgroup.
Conclusions: A single measurement of suPAR on admission can provide prognostic information for patients with suspected COVID-19 pneumonia. In the subgroup of patients with positive real-time PCR result for SARS-CoV2, suPAR was significantly higher and had an excellent prognostic value for the in-hospital mortality.
Keywords: Biomarker; COVID-19; Chest infection; Prognosis; suPAR.